Section Edited by Jason J. Luke, MD, FACP and Douglas G. McNeel, MD, PhD
Clinical trials: prospective studies including first-in-man clinical trials, phase II/III clinical studies, and immune monitoring investigations. Small, single institution-based retrospective reports are discouraged.
Preclinical studies: studies that lead to mechanistic understanding or novel development of agents and combination therapies directly relevant to human immunotherapy.
AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumorsSophia Frentzas, Steven Kao, Rang Gao, Hao Zheng, Ahsan Rizwan, Nageshwar Budha, Luz de la Hoz Pedroza, Wei Tan, Tarek Meniawy
19 October 2023
Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancerAbdul Rafeh Naqash, Justin D McCallen, Emma Mi, Sanna Iivanainen, Mona A Marie, Daria Gramenitskaya, James Clark, Jussi Pekka Koivunen, Shravanti Macherla, Sweta Jonnalagadda, Shanker Polsani, Rahim Ali Jiwani, Maida Hafiz, Mahvish Muzaffar, Leonardo BrunettiSee the full list of authors
18 October 2023
Phase II trial of nivolumab and metformin in patients with treatment-refractory microsatellite stable metastatic colorectal cancerMehmet Akce, Batoul Farran, Jeffrey M Switchenko, Manali Rupji, Sandra Kang, Lana Khalil, Amanda Ruggieri-Joyce, Brian Olson, Walid L Shaib, Christina Wu, Olatunji B Alese, Maria Diab, Gregory B Lesinski, Bassel F El-Rayes
18 October 2023
Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinomaPhilip Clingan, Rahul Ladwa, Daniel Brungs, Dean Laurence Harris, Margaret McGrath, Susan Arnold, Jermaine Coward, Samuel Fourie, Andriy Kurochkin, Daniel R Malan, Andrew Mant, Vinay Sharma, Hong Shue, Andrea Tazbirkova, Miguel-Angel Berciano-GuerreroSee the full list of authors
17 October 2023
PD-1 blockade in combination with dasatinib potentiates induction of anti-acute lymphocytic leukemia immunityPaul Koller, Natalia Baran, Karine Harutyunyan, Antonio Cavazos, Saradhi Mallampati, Renee L Chin, Zhou Jiang, Xian Sun, Heng-Huan Lee, Jennifer L Hsu, Patrick Williams, Xuelin Huang, Michael A Curran, Mien-Chie Hung, Marina Konopleva
4 October 2023
Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastomaChiara Brignole, Enzo Calarco, Veronica Bensa, Elena Giusto, Patrizia Perri, Eleonora Ciampi, Maria Valeria Corrias, Simonetta Astigiano, Michele Cilli, Derik Loo, Ezio Bonvini, Fabio Pastorino, Mirco Ponzoni
28 September 2023
Bispecific antibody CD73xEGFR more selectively inhibits the CD73/adenosine immune checkpoint on cancer cells and concurrently counteracts pro-oncogenic activities of CD73 and EGFREmily Maria Ploeg, Douwe Freerk Samplonius, Xiao Xiong, Xiurong Ke, Mark Alexander Johannes Martinus Hendriks, Isabel Britsch, Anne Paulien van Wijngaarden, Hao Zhang, Wijnand Helfrich
21 September 2023
Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trialWenwen Zhang, Shuang Tong, Bingyang Hu, Tao Wan, Haowen Tang, Feilong Zhao, Tianyu Jiao, Junfeng Li, Ze Zhang, Jinping Cai, Huiyi Ye, Zhanbo Wang, Shiqing Chen, Yafei Wang, Xuerui LiSee the full list of authors
20 September 2023
Treatment management for BRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREGMaximilian Haist, Henner Stege, Friederike Rogall, Yuqi Tan, Imke von Wasielewski, Kai Christian Klespe, Friedegund Meier, Peter Mohr, Katharina C Kähler, Michael Weichenthal, Axel Hauschild, Dirk Schadendorf, Selma Ugurel, Georg Lodde, Lisa ZimmerSee the full list of authors
19 September 2023
Responses of patients with cancer to mRNA vaccines depend on the time interval between vaccination and last treatmentLara Victoria Donhauser, Julia Veloso de Oliveira, Cordula Schick, Wenzel Manlik, Sabrina Styblova, Sarah Lutzenberger, Michael Aigner, Patrick Philipp, Sebastian Robert, Beate Gandorfer, Dirk Hempel, Louisa Hempel, Dietmar Zehn
19 September 2023